Clinical trial of tocilizumab for skin fibrosis in systemic sclerosis (Ver. Osaka)
Not Applicable
- Conditions
- Systemic sclerosis
- Registration Number
- JPRN-UMIN000015495
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who are administered the other biologics 2)Patients who have history of anaphylactic reactions to this drug 3)Patients who have HBV or who are under the septic condition 4)significant liver damage 5)significant renal damage 6)possibility of tuberculosis 7)pregnancy 8)breast-feeding 9)participating in other clinical trial within three months before the beginni ng of this trial 10)judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sum of skin scores from 17 sites of the body (modified Rodnan total skin score)
- Secondary Outcome Measures
Name Time Method Skin hardness, elasticity, and viscosity evaluate by Vesmter